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During recent years, a syndrome of hypokinesia, dysarthria, dystonia, and postural impairment, related to intravenous use
of a “designer” psychostimulant derived from pseudoephedrine using potassium permanganate as the oxidant, has been
observed in drug addicts in several countries in Eastern Europe with some cases also in Western countries. A levodopa
unresponsive Parkinsonian syndrome occurs within a few months of abusing the homemade drug mixture containing ephedrone
(methcathinone) and manganese. The development of this neurological syndrome has been attributed to toxic eﬀects of
manganese, but the role of the psychostimulant ephedrone is unclear. This paper describes the clinical syndrome, results of
neuroimaging,and therapeutic attempts.
1.Introduction
Manganese (Mn) is an essential trace metal, present in most
tissues.ExcessiveexposuretoMnmaycausethedevelopment
of a Parkinsonian syndrome known as manganism. The
symptoms of chronic Mn intoxication were ﬁrst reported
by Couper in workers inhaling “black oxide of manganese”
in an ore-grinding plant [1]. He described a diﬃculty of
movement as paraplegia, accompanied by lack of facial
expression, drooling, and impaired speech.
Mniswidelyusedinindustryandisfoundincommercial
products and industrial settings. Occupational inhalational
exposure, especially in mining [2], smelting [3], and welding
[4], has been the main cause of human Mn intoxication. Mn
is used in the manufacture of steel and batteries, bactericidal
agents,gasoline,andthewaterpuriﬁcationprocess.Mangan-
ism has also been described in nonoccupational settings, like
long-term total parenteral nutrition [5], chronic liver failure
[6], or exposure to contaminated well water [7].
Parkinsonism is a characteristic clinical manifestation of
manganism, typically with symmetric bradykinesia, rigidity,
gait disorder and falls, speech disturbance and sometimes
with the presence of postural or action tremor. Dystonias
in the face and limbs may develop; behavioural and cog-
nitive changes have been described in the early course [8].
Blood manganese concentration reﬂects current exposure,
and magnetic resonance imaging (MRI) typically shows
accumulation of Mn in the brain, causing hyperintensity in
T1-weighted sequences, mainly in the basal ganglia [9, 10].
Parkinsonism caused by Mn exposure does not respond to
levodopa treatment, but chelating therapy with calcium salt
ofethylenediamine tetraaceticacid (CaNa2EDTA)maybe of
clinical beneﬁt [11].
During the recent years, a levodopa unresponsive
Parkinsonian syndrome associated with early falls, severe
dysarthria, and prominent limb dystonia, has been described
in individuals who have chronically administered a “de-
signer” psychostimulant ephedrone (methcathinone) intra-
venously. The syndrome closely resembles a chronic man-
ganic encephalopathy seen in manganese ore miners. Ephe-
drone, the oxidation product of ephedrine or pseudoephed-
rine, is a psychostimulant that has become a substantial
drug of abuse in several countries [12]. The ﬁrst cases of
“ephedrone encephalopathy” were described in the Russian
literature 20 years ago but this topic has gained growing
international interest as several case series from Eastern
Europe [13–17] and also some immigrant cases from
Western Europe and Canada have been reported [18, 19].
It is diﬃcult to estimate the scope of ephedrone
abuse and the prevalence of Mn-induced parkinsonism
among abusers. According to a survey performed by the
National Institute for Health Development in Estonia with2 Parkinson’s Disease
a population of 1.34 million, there were approximately
13800 intravenous drug users in Estonia, among them 10000
living in Tallinn and its neighbouring areas, and 2500 in
the north-eastern part of Estonia [20]. In a survey on risk
behaviour in these areas, 700 intravenous drug users in
Tallinn and Eastern Estonia were interviewed: 11% of the
participants reported ephedrone use in their history, and
1.3% were current users [21].
The development of the neurological syndrome in
ephedrone addicts has been largely attributed to the toxic
eﬀects of Mn. This is supported by the clinical signs that
are consistent with the occupational manganism, and by
the fact that Parkinsonian syndrome did not develop when
ephedrone users had prepared the drug using potassium or
sodium dichromate as the oxidation agent instead of potas-
sium permanganate. This diﬀerent chemical preparation
has been observed in US clandestine laboratories, followed
by several cleanup steps; the powder has been inhaled or
sniﬀed, and an acute toxicity has been described as similar
to amphetamine-like drugs but no neurologic sequelae have
been reported [22].
The role ofthepsychostimulant ephedronein developing
Parkinsonism is unclear, as are the pathophysiological and
pathoanatomical mechanisms of damage caused by the
mixture. It is, however, possible that ephedrone itself may
have pathogenic eﬀects on nigral neurons compounding the
risk; it aﬀects the dopaminergic transporter in a manner
resembling that of methamphetamine and causes increased
dopamine release. Despite the absence of clinical signs of
parkinsonism, dopaminergic dysfunction has been shown in
abusersofthe psychostimulants ephedrone (methcathinone)
and methamphetamine, which are chemically related as
methamphetamine is a reduction product of ephedrine
or pseudoephedrine: [11C]WIN-35,428-PET study demon-
strated a signiﬁcant reduction in DAT density in caudate
nucleus and putamen [23]. These ﬁndings have raised
concerns that these psychostimulants may increase the risk
of development of Parkinson’s disease.
Historically, intravenous use of 1-methyl-4-phenyl-
1,2,5,6-tetrahydropyridine (MPTP), also known as a “syn-
thetic heroin”, has caused a severe Parkinsonian syndrome
with rigidity, hypokinesia, gait disorder, and hallucinations
within some weeks after starting injections of the drug. In
[18F]ﬂuorodopa PET, there was a reduction of dopaminergic
function in the caudate and putamen in MPTP users and
levodopa therapy was eﬀective [24, 25]. Discovering of the
ability of MPTP to produce selective nigral cell degeneration
and parkinsonism in humans has been probably the greatest
advance in experimental models of parkinsonism [26].
In the animal experiments, ephedrone had a strong
stimulating eﬀect in mice but during chronic administration
of the drug, neither parkinsonism nor dystonias developed
[27]. In a doseresponse study, thelethal outcomewas caused
by the lower doses of ephedrone as part of the mixture
compared to pure ephedrone, which indicates the possible
role of a neurotoxic potentiation by the components in the
mixture [28].
To evaluate neurotoxicity of Mn and psychostimu-
lants, experiments on nonhuman primates have been used
includingneuroimaging,neurochemicalandneuropatholog-
ical investigations. Nonhuman primates exposed to several
sequential doses of psychostimulant 3,4-methylendioxy-
methamphetamine (MDMA, “Ecstasy”), developed severe
brain dopaminergic neurotoxicity, additionally to less
pronounced serotonergic neurotoxicity—it suggests that
humans using MDMA are at high risk for brain dopamin-
ergic injury [29]. In a nonhuman primate study, chronic
Mn exposure resulted in a subtle motor function deﬁcit but
a marked decrease of dopamine release in the absence of
terminal loss [30]. A longitudinal PET study in Mn-exposed
nonhuman primates that included the administration of
amphetamine indicated that motor function abnormalities
are likely mediated by inhibition of dopamine release in the
striatum [31].
The extrapyramidal syndrome in abusers of ephedrone
has been referred to be caused by toxicity of high Mn
load but despite the lack of evidence to link ephedrone
with an increased risk for parkinsonism, it may have a
potential to increase the risk of damage from manganese
exposure.
2.Synthesis and ChemicalAnalysis
of Ephedrone
Ephedrone is a psychostimulant drug that increases the
release of catecholamines in the brain and has similar
behavioural eﬀects to methamphetamine. It is a synthetic
N-methyl analogue of cathinone which is found in the
leaves of the khat bush (Catha edulis). Ephedrone causes
acute eﬀects including euphoria, agitation, anxiety, and
hallucinations, similarly to methamphetamine and other
amphetamines [12, 22].
Ephedrone mixture for injection is synthesised by the
drug addicts from over-the-counter cold remedies contain-
ing ephedrine or pseudoephedrine (Sudafed). Potassium
permanganate and acetic acid are added for inducing the
oxidation. The solution made with boiling water is cooled,
ﬁltered through a cotton pad, and injected intravenously.
Only 44% of pseudoephedrine was converted to ephedrone
in the reaction. The concentration of Mn in the ﬁnal
synthetic mixture was found to be very high −0.6g/L
[14].
When injected dozens of times per day with a daily
injection volume of 100–300mL, the daily load of Mn is
60–180mg, an enormous overload compared to the recom-
mended dose of 0.1mg of Mn as a maximum intravenous
daily supplementation [32]. The estimated ephedrone con-
tent in the mixture is 4.4mg/mL, and thus the daily load is
400–1200mg of ephedrone. Instructions on how to produce
this neurotoxic mixture are readily available on the Internet
in several languages, and are widely spread among drug
addicts. The ephedrone mixture has also been referred to as
“Russian Cocktail”, and by its street names “cat”, “mulka”,
“murtsovka”, and “Jeﬀ”. Making the drug is simple, all
necessary components can be bought from the pharmacy
without a prescription, and the instructions for preparation
are readily available on the Internet.Parkinson’s Disease 3
3.Symptoms
The ﬁrst neurological symptoms—usually gait disturbance
and slurred speech—have occurred only some months after
the beginning of ephedrone injections [15]o ru pt o1 7y e a r s
later [17], but generally within the ﬁrst few years. There
is no correlation between the duration of drug abuse and
clinical severity, and in some abusers, the syndrome does not
developatall,despiteephedroneuse.The mostcharacteristic
reported neurological ﬁndings were postural instability with
retropulsion and falls, gait disturbance, hypomimia, limb
and face dystonia, dysarthria, hypophonia, and symmetric
bradykinesia. Less frequently described symptoms were
limb and axial rigidity, gait freezing, postural and resting
tremor, micrographia, apraxia of eyelid opening, some
slowing of vertical saccades, pathological laughter, palilalia,
and primitive reﬂexes (Table 1). Though hyperactive deep
tendon reﬂexes were common ﬁndings, pathological reﬂexes
were mentioned only in one case [18]. Few cases had
oromandibular dyskinesia, blepharospasm [37], myoclonus
[33], or restriction of vertical saccadic eye movements [19].
Most authors have used the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) for scoring motor function though
it does not reﬂect the disability in details because some
prominent symptoms are diﬀerent from Parkinson’s disease.
Compared to Parkinson’s disease, the disability in the
ephedrone abusers is mainly caused by postural and gait
impairment and dystonias in a relatively early phase of the
disease. In UPDRS, only a few items in the motor score are
related to gait and postural impairment, and there are more
items for evaluation of tremor that is not characteristic sign
for parkinsonism in ephedrone users. Combining UPDRS
with Hoehn and Yahr staging, Schwab and England rating
scale, and Parkinson’s Disease Quality of Life Questionnaire
gives better assessment of the syndrome severity.
The scores of the Mini Mental State Examination
were normal. More extensive neuropsychological testing
showed mild executive cognitive impairment including
bradyphrenia, attenuated attention, reduced working capac-
ity, decreased phonetic verbal ﬂuency, and tendency to
impulsiveness [16, 18, 33, 36].
After drug abuse discontinuation, usually there was no
change, or there was even further progression of the motor
impairment, but a few patients had slight improvement of
their symptoms.
4.Manganese Concentration
Chronic exposure causes accumulation of Mn in blood
and tissues. Active ephedrone users had increased levels
of blood Mn (average 831nmol/L, range 201–2102) but
former users had normal or slightly elevated blood Mn
values (average 346nmol/L, range 114–727) [17]. Elevated
Mn blood concentration was a characteristic feature that
indicated continuing abuse of ephedrone; there was a
signiﬁcant diﬀerence when compared to the former drug
users.
Manganese is eliminated rapidly from the blood, and
thusbloodlevelsofMnmaypoorlyreﬂect tissueMncontent.
InaUkrainian study,scalphairlevelshowed overlapbetween
controls and ephedrine-exposed cases but pubic hair Mn
concentration was signiﬁcantly elevated in patients with
less than one year oﬀ ephedrone abuse (1.94±1.60µg/g)
compared with the controls (0.34±1.60µg/g) [16].
5.Neuroimaging
Magnetic resonance imaging (MRI) of the brain in active
ephedrone users showed symmetrical hyperintensity on
T1-weighted images in the globus pallidus and substantia
nigra pars reticulata (Figure 1). Less frequently involved
structures were subthalamic nucleus, substantia innominata,
putamen, caudate, anterior midbrain, pontine tegmentum,
and dentate nucleus. In former users, the signal increase is
less intense and not so widespread. MRI was already normal
six months after the last exposure to ephedrone [37]. Some
cases had increased signal intensity up to six years after
cessation of drug abuse [17]. However, these cases had high
concentration of Mn in blood, which could refer to other
susceptibility factors like chronic liver disease or even to the
continuous drug abuse.
Although MRI T1-weighted scans did not show abnor-
malities of white matter, diﬀusion tensor imaging has
demonstrated widespread white matter abnormalities, par-
ticularly in central white matter and areas underlying
the right ventral premotor cortex and medial prefrontal
premotor cortex [38]. The detection of these abnormalities
outside areas known to be connected directly to the globus
pallidus suggests a more widespread neuronal pathology
than previously demonstrated by conventional imaging
techniques.
Single-photonemission computedtomography(SPECT)
imaging with 123I Ioﬂupane (DaTSCAN) was performed in
10 former ephedrone addicts in three diﬀerent centres and it
showed a normal pattern of tracer uptake in all of the cases
[16, 18, 34].
6-Fluorodopa positron emission tomography (PET) in
an active user revealed a mild reduction in presynaptic
uptake limited to the posterior putamen [19]. This minor
change could be adaptive to psychostimulant abuse. Fluo-
rodeoxyglycose (FDG) PET in four former users showed a
widespread butnotuniformdecrease oftraceruptakemainly
in the basal ganglia and the surrounding white matter [34].
6.ConcomitantInfections
The possible role of concomitant infections has been
emphasised as parkinsonism may represent a manifestation
of human immunodeﬁciency virus (HIV) encephalopathy.
Clinically relevant movement disorders are not common in
patients with HIV infection [39]; parkinsonism has been
observed in 5% of HIV positive patients [40].
In the Latvian study with the highest number of the
patients among the reports on ephedrone abuse, 20 of 23
patients (87%) were positive for the HIV, and 45% of
them had acquired immunodeﬁciency syndrome (AIDS).
However, progressive Parkinsonian syndrome occurred also4 Parkinson’s Disease
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Figure 1: T1-weighted axial MRIs of the brain showing an increased signal in the globus pallidus in an active user and and two years after
cessation of exposure.
in HIV-negative ephedrone users. Parkinsonian disorder
in HIV encephalopathy is often related to HIV-associated
dementia but the ephedrone users had normal cognitive
function [17].
All the patients were positive for hepatitis C virus that
is considered as a possible cause for extrapyramidal disease.
Similar changes in the globus pallidus as described in
ephedroneaddicts, havebeenshown in patients with chronic
hepatic disease and cirrhosis, but liver failure or cirrhosis
have not been reported in any of the patients [17, 35]. Thus,
concomitant infectious diseases have no direct eﬀect to the
movement disorder that occurs as a consequence of illicit
use of ephedrine, but they are related to the contamination
during intravenous injection of drugs.
7.Treatment
The acute levodopa challenge tests were negative. Chronic
levodopa therapy up to the maximum tolerated doses
showed no improvement. Dopamine agonists were ineﬀec-
tive as well [18, 19]. Some patients reported subjective short-
term improvement with amantadine [16]. There was no
change [18], or there was a mild reduction [16]i nd y s t o n i c
symptoms with anticholinergic drugs.
Chelating treatment with ethylenediaminetetraacetic
acid (EDTA) reduced blood Mn levels, but did not aﬀect
symptoms [17, 37], or led to a mild improvement probably
related to abstinence [15, 16]. Para-aminosalicylic acid
(PAS),anothermedication with chelating properties, did not
change clinical ﬁndings [37].
Generally, the syndrome is unresponsive to levodopa
and other antiParkinsonian medication, and there is also no
other eﬀective treatment that could continuously improve
Parkinsonian or dystonic symptoms in the ephedrone users.
Even when mild improvement observed, it has been in the
short-term, and the condition may worsen progressively
despite discontinuation of injecting the drug.
8.Conclusions
Mn-induced extrapyramidal system damage develops in
ephedrone abusers due to the accumulation of Mn in the
basal ganglia. Ephedrone could have additive neurotoxic
eﬀect to the progression of parkinsonism, but the existing
evidence is inconclusive. Concomitant infections have no
direct eﬀect on the development of the syndrome. Man-
ganese metabolism in blood is fast, tissue concentrations
remain high much longer. Functional neuroimaging studies
and lack of levodopa response conﬁrm that the presynaptic
neurons in the nigrostriatal pathway are intact. According
to FDG PET study, changes in brain metabolism are more
widespread mainly located in the central part of the brain
including the basal ganglia, thalami, and the surrounding
white matter.
Ephedrone addiction is an alarming new cause of toxic
parkinsonism. Ephedrone is a widespread recreational drug
because it is relatively cheap and easy to prepare. The
described cases could be just “the tip of the iceberg”. In the
most extreme cases, only a few months of ephedrone abuse
could lead to severe and progressing disability.
The prognosis of the Parkinsonian syndrome in
ephedrone users is poor as there is no curative therapy. The
addicts seem to be unaware of the long-term side eﬀects and
deterioration. Though presently reported mainly in Eastern
Europe,a globalspreadmight occur,and thediagnosisneeds
to be considered within the social risk groups anywhere.Parkinson’s Disease 7
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